Context Therapeutics’ (CNTX) Buy Rating Reiterated at D. Boral Capital

Context Therapeutics (NASDAQ:CNTX)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $9.00 target price on the stock. D. Boral Capital’s price target points to a potential upside of 180.46% from the stock’s current price.

A number of other equities analysts also recently issued reports on the stock. Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. Piper Sandler boosted their price objective on shares of Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday. JonesTrading began coverage on Context Therapeutics in a report on Monday, December 22nd. They set a “buy” rating and a $7.00 target price for the company. Guggenheim reaffirmed a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a research report on Tuesday. Finally, Wall Street Zen raised Context Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.60.

Context Therapeutics Stock Up 6.3%

Shares of CNTX stock traded up $0.19 on Tuesday, hitting $3.21. The stock had a trading volume of 539,933 shares, compared to its average volume of 1,675,144. Context Therapeutics has a one year low of $0.49 and a one year high of $3.62. The business has a 50 day moving average price of $2.38 and a 200 day moving average price of $1.58. The company has a market cap of $294.84 million, a PE ratio of -13.38 and a beta of 1.97.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Monday, March 23rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.04). Equities research analysts expect that Context Therapeutics will post -0.51 EPS for the current year.

Hedge Funds Weigh In On Context Therapeutics

Large investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in shares of Context Therapeutics during the 4th quarter valued at $43,000. Quadrature Capital Ltd acquired a new position in Context Therapeutics during the 4th quarter valued at about $68,000. Clear Harbor Asset Management LLC increased its position in Context Therapeutics by 60.5% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after buying an additional 35,000 shares in the last quarter. XTX Topco Ltd raised its stake in Context Therapeutics by 858.8% in the fourth quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after buying an additional 91,008 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in Context Therapeutics in the third quarter worth about $100,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Context Therapeutics

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target from $4.00 to $7.00 and kept an “overweight” rating — a large upside projection that can attract buyers and drive momentum. Benzinga
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and set a $5.00 target, another analyst endorsement boosting investor confidence. Benzinga
• Positive Sentiment: Clear near‑term catalysts: interim Phase 1a data for CTIM‑76 expected in June 2026 and for CT‑95 in September 2026, plus a planned CT‑202 first dosing in Q3 2026 — events that could materially re‑rate the stock if data are positive. GlobeNewswire
• Positive Sentiment: Context reports $66.0M cash (as of 12/31/2025), which management says should fund operations into mid‑2027 — reduces near‑term financing risk ahead of upcoming readouts. QuiverQuant
• Neutral Sentiment: Company updated its corporate presentation highlighting the evolving T‑cell engager pipeline — useful for investors but dependent on forthcoming clinical data for market impact. TipRanks
• Neutral Sentiment: Reported short‑interest data appear unreliable (entries show 0 shares / NaN change) and currently don’t provide a clear signal.
• Negative Sentiment: Recent quarterly results showed an EPS miss (reported ($0.14) vs. consensus ($0.10)) — a short‑term negative that could cap upside if execution slips.
• Negative Sentiment: Financial pressures: net loss widened to $36.1M in 2025 and cash declined from $94.4M to $66.0M year‑over‑year; higher R&D spend increases burn — may force future dilution if trials are prolonged or readouts negative. GlobeNewswire

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.